Coronavirus: PM Modi to interact with 3 teams developing COVID-19 vaccine
The Prime Minister's Office said in a tweet on Sunday that the three teams are from Gennova Biopharma, Biological E and Dr Reddy's.
<p>Prime Minister Narendra Modi will interact with three teams involved in developing COVID-19 vaccine via video conferencing on Monday.<br /> </p>
Prime Minister Narendra Modi will interact with three teams involved in developing COVID-19 vaccine via video conferencing on Monday.
<p>The Prime Minister's Office said in a tweet on Sunday that the three teams are from Gennova Biopharma, Biological E and Dr Reddy's.</p>
The Prime Minister's Office said in a tweet on Sunday that the three teams are from Gennova Biopharma, Biological E and Dr Reddy's.
<p>"Tomorrow, on 30th November, 2020, PM @narendramodi will interact, via video conferencing, with three teams that are involved in developing a COVID-19 vaccine. The teams he will interact with are from Gennova Biopharma, Biological E and Dr Reddy's," it said.</p><p> </p>
"Tomorrow, on 30th November, 2020, PM @narendramodi will interact, via video conferencing, with three teams that are involved in developing a COVID-19 vaccine. The teams he will interact with are from Gennova Biopharma, Biological E and Dr Reddy's," it said.
<p>Modi had on Saturday visited biotechnology companies Zydus Cadila, Bharat Biotech and Serum Institute of India in Ahmedabad, Hyderabad and Pune to take stock of the developmental stage of the vaccines.</p><p> </p>
Modi had on Saturday visited biotechnology companies Zydus Cadila, Bharat Biotech and Serum Institute of India in Ahmedabad, Hyderabad and Pune to take stock of the developmental stage of the vaccines.
<p>Prime Minister Narendra Modi on Saturday visited the facilities of three biotechnology companies that are testing different COVID-19 vaccine candidates.</p><p> </p>
Prime Minister Narendra Modi on Saturday visited the facilities of three biotechnology companies that are testing different COVID-19 vaccine candidates.
<p>The companies, two of which have begun Phase 3 trials in thousands of volunteers, are expected to manufacture millions of doses in the first half of 2021 if the candidates pass regulatory muster.</p>
The companies, two of which have begun Phase 3 trials in thousands of volunteers, are expected to manufacture millions of doses in the first half of 2021 if the candidates pass regulatory muster.